Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva], Alendronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years and older · Female only
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Riverside, California • Lakewood, Colorado + 12 more
Completed Phase 2 Interventional Results available

Romosozumab in Women With Chronic SCI

NCT04708886
Conditions
Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis
Interventions
Romosozumab, Alendronate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Alendronate, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
alendronate sodium, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
IOP, Osteoporosis
Interventions
Alendronate, Zoledronic Acid
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Conditions
HIV Infection
Interventions
Alendronate, Placebo, Calcium carbonate/vitamin D
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
11 Years to 24 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
Conditions
Osteopenia, Osteoporosis
Interventions
alendronate sodium, placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Bone Loss
Interventions
Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Winston-Salem, North Carolina
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Completed Phase 4 Interventional Accepts healthy volunteers

Bone Loss in Premenopausal Women With Depression

NCT00006180
Conditions
Depression, Healthy, Osteopenia, Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 45 Years · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gaucher's Disease, Osteopenia
Interventions
alendronate sodium, calcium carbonate, cholecalciferol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Cincinnati, Ohio • Dayton, Ohio
Conditions
Healthy
Interventions
Alendronate Sodium Tablets, 10 mg, Fosamax Tablets, 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Osteoporosis, Cardiac Transplantation
Interventions
Alendronate, Calcitriol, Placebo Alendronate, Placebo Calcitriol
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 70 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
2
States / cities
New York, New York
Conditions
Osteopenia, Osteoporosis, Osteonecrosis
Interventions
LLP2A-ALENDRONATE, Placebo
Drug
Lead sponsor
Nancy E. Lane, MD
Other
Eligibility
20 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Cypress, California • Walnut Creek, California • Duncansville, Pennsylvania + 1 more
Completed No phase listed Observational Accepts healthy volunteers

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

NCT00221312
Conditions
Perimenopausal Bone Loss
Interventions
Fosamax
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 54 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Results available

Transition From Alendronate to Romosozumab (AMG 785)

NCT01588509
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
15
States / cities
Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more
Conditions
Osteoporosis
Interventions
Parathyroid Hormone, Alendronate, Teriparatide
Drug
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2006
U.S. locations
1
States / cities
West Haverstraw, New York
Conditions
Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 14 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Not applicable Interventional Results available

Renal Osteodystrophy: An Individual Management Approach

NCT02440581
Conditions
Kidney Failure, Chronic
Interventions
Alendronate, Teriparatide, Cinacalcet
Drug
Lead sponsor
Hartmut Malluche, MD
Other
Eligibility
21 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Osteoporosis
Interventions
DMAB Discontinuation and Switching
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Postmenopausal Women With Osteoporosis
Interventions
Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
4,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Conditions
Polyostotic Fibrous Dysplasia
Interventions
Fosamax (Alendronate)
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland